George Jaiben, Gautam Deepak, Sugumar PonAravindhan A, Janardhanan Ritvik, Kabra Apoorva, Malhotra Rajesh
Department of Orthopedic Surgery, AIIMS, New Delhi, India.
J Clin Orthop Trauma. 2022 May 13;29:101894. doi: 10.1016/j.jcot.2022.101894. eCollection 2022 Jun.
The presence of geographic and demographic disparities in randomized controlled trials (RCTs) may affect the external validity of trials. While some studies have addressed racial or ethnic disparities, they have been limited to a certain region, and there is limited information about the global representation in orthopaedic research.
RCTs published in major medical and orthopaedic journals from 2010 to 2019 were identified. After screening 6961 articles, 1769 trials enrolling 323,506 patients were included. The details of individual trials such as the country of origin, the proportion of women, and the proportion of different racial groups were recorded. Factors associated with reporting and representation of specific demographic groups, and annual changes were assessed.
Majority of the trials were from were from United States (US) (N = 380, 21.5%). US (30.7%, N = 99,356), United Kingdom (15.7%, N = 50,691) and Canada (8.3%, N = 26,890) accounted for majority of the enrolled patients. 59.1% of the patients were women. Among US trials reporting race, 81.2% were White, and 9.9% were African American. There was no significant variation in the global distribution (p = 0.056), percentage of women (p = 0.811), or percentage of Whites (p = 0.389) over the years.
The top three countries contributed to about 55% of the enrolled patients, whereas they contributed to only 6% of the world population. Overall, women appeared to be adequately represented in the trials, while racial minorities were underrepresented. There has not been any considerable improvement in the representation of developing regions or minorities over the last decade.
随机对照试验(RCT)中地理和人口统计学差异的存在可能会影响试验的外部有效性。虽然一些研究探讨了种族差异,但这些研究仅限于特定地区,关于骨科研究中全球代表性的信息有限。
确定2010年至2019年在主要医学和骨科期刊上发表的随机对照试验。在筛选6961篇文章后,纳入了1769项试验,共涉及323506名患者。记录了各个试验的详细信息,如原产国、女性比例和不同种族群体的比例。评估了与特定人口群体报告和代表性相关的因素以及年度变化。
大多数试验来自美国(N = 380,21.5%)。美国(30.7%,N = 99356)、英国(15.7%,N = 50691)和加拿大(8.3%,N = 26890)的试验纳入了大多数患者。59.1%的患者为女性。在美国报告种族的试验中,81.2%为白人,9.9%为非裔美国人。多年来,全球分布(p = 0.056)、女性比例(p = 0.811)或白人比例(p = 0.389)没有显著变化。
排名前三的国家贡献了约55%的纳入患者,而它们仅占世界人口的6%。总体而言,试验中女性的代表性似乎充足,而少数族裔的代表性不足。在过去十年中,发展中地区或少数族裔的代表性没有任何显著改善。